TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07816666: A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epith

Sponsor: AstraZeneca · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT07816666 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07816666 Rescue Dossier →